Guinea Pig: SB 239063 (3, 10, or 30 mg/kg) was administered intragastrically via feeding tube 1 h before and 4 h after LPS challenge. For airway neutrophilia and IL-6 recovery experiments (48-h studies), SB 239063 was administered twice, 6 h apart, on the day after LPS challenge. For MMP-9 and IL-6 recovery experiments (6-h studies), SB 239063 (30 mg/kg) was administered 1 h before and 4 h after LPS challenge. Rats: SB 239063 were administered orally, followed 60 min later by a challenge with LPS (3.0 mg/kg ip). For time-course studies, 15 mg/kg of SB 239063 were administered orally 1, 2, 3, or 4 h before LPS challenge.

During the treatment with 20 μM and 100 μM SB239063 of hippocampal slice cultures, was observed significantly reduction of the levels of the pro-inflammatory cytokine IL-1beta and reduction of cell death after oxygen-glucose deprivation, in addition was seen strikingly diminishing of microglia activation